Filgrastim is a recombinant version of the naturally occurring G-CSF that stimulates neutrophil production. It was licensed for the treatment of low blood neutrophils in the U.S. in 1991. The World Health Organization (WHO) declared Filgrastim in the List of Essential Medicines as safe and most effective medicine. Filgrastim was first discovered by Amgen, Inc. and sold under the brand name Neupogen. Large number of biosimilar companies are engaged in the manufacture and marketing of Filgrastim across the world. Filgrastim costs around $200 in the U.S, around 50 Euro in the UK, and $100 in developing countries.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐨𝐟 𝐅𝐢𝐥𝐠𝐫𝐚𝐬𝐭𝐢𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 – 𝐂𝐎𝐕𝐈𝐃-19 𝐈𝐦𝐩𝐚𝐜𝐭 𝐚𝐧𝐝 𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐰𝐢𝐭𝐡 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐭: https://www.alliedmarketresearch.com/request-sample/3643
Factors such as increase in prevalence of various diseases and rising elderly population are driving thegrowth of filgrastim market. Moreover, increasing pressure to reduce healthcare expenditure and rising demand for filgrastim owing to its cost-effectiveness is expected to fuel the growth of this market. Moreover, increasing demand for biosimilars for the treatment of neutropenia further inhibits the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting, which hinder the market growth. Conversely, increase in substantial investment in R&D activities to develop effective and innovative biosimilars will provide further opportunities to the market.
In addition, this drug is used to treat neutropenia, a condition that occurs after bone marrow transplantation and chemotherapy. It has been used to treat a variety of malignancies as supportive therapy. Over the past decade, cancer prevention has increased dramatically in developed countries, and governments have launched campaigns to raise awareness of early treatment. These reasons are expected to drive the global filgrastim market. Approved biosimilars such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper and readily available in developing countries, are expected to fuel the growth of the global filgrastim market.
𝐅𝐢𝐥𝐠𝐫𝐚𝐬𝐭𝐢𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧
The global filgrastim market is segmented on the basis of drug type, distribution channel, indication, and region. On the basis of drug type, it is further classified into biologics and biosimilars. On the basis of distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. On the basis of indication, it is categorized into chemotherapy-induced neutropenia, chronic neutropenia, and others. By region, the market is analyzed into North America, Europe, Asia Pacific, and LAMEA.
𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:https://www.alliedmarketresearch.com/purchase-enquiry/3643
𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐨𝐟 𝐅𝐢𝐥𝐠𝐫𝐚𝐬𝐭𝐢𝐦 𝐌𝐚𝐫𝐤𝐞𝐭
1. Abbott Laboratories
4. Cadila Pharmaceuticals
5. Dr. Reddy’s Laboratories
6. Kirin Holding (Kyowa Kirin)
9. Teva Pharmaceutical Industries Ltd.
10. Toksöz Group
𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬
𝐁𝐲 𝐃𝐫𝐮𝐠 𝐓𝐲𝐩𝐞
𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥
𝐂𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧𝐝𝐮𝐜𝐞𝐝 𝐍𝐞𝐮𝐭𝐫𝐨𝐩𝐞𝐧𝐢𝐚
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
𝐇𝐚𝐯𝐞 𝐚 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧? 𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/connect-to-analyst/3643
𝐅𝐑𝐄𝐐𝐔𝐄𝐍𝐓𝐋𝐘 𝐀𝐒𝐊𝐄𝐃 𝐐𝐔𝐄𝐒𝐓𝐈𝐎𝐍𝐒?
Q1. What is the total market value of Filgrastim market report ?
Q2. What would be forecast period in the market report?
Q3. What is the market value of Filgrastim market in 2021?
Q4. Which is base year calculated in the Filgrastim market report?
Q5. Which are the top companies hold the market share in Filgrastim market?
Q6. Which is the most influencing segment growing in the filgrastim report?
Q7. What are the key trends in the Filgrastim market report?
Q8. What are the market values / growth % of emerging countries?